David V Morrissey

Summary

Affiliation: Sirna Therapeutics
Country: USA

Publications

  1. ncbi request reprint Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication
    David V Morrissey
    Sirna Therapeutics, Inc, Boulder, CO 80301, USA
    Hepatology 41:1349-56. 2005
  2. ncbi request reprint Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs
    David V Morrissey
    Sirna Therapeutics, Inc, 2950 Wilderness Place, Boulder, Colorado 80301, USA
    Nat Biotechnol 23:1002-7. 2005

Detail Information

Publications2

  1. ncbi request reprint Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication
    David V Morrissey
    Sirna Therapeutics, Inc, Boulder, CO 80301, USA
    Hepatology 41:1349-56. 2005
    ..In conclusion, these experiments establish the strong impact that siRNAs can have on the extent of HBV infection and underscore the importance of stabilization of siRNA against nuclease degradation...
  2. ncbi request reprint Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs
    David V Morrissey
    Sirna Therapeutics, Inc, 2950 Wilderness Place, Boulder, Colorado 80301, USA
    Nat Biotechnol 23:1002-7. 2005
    ..The advances demonstrated here, including persistence of in vivo activity, use of lower doses and reduced dosing frequency are important steps in making siRNA a clinically viable therapeutic approach...